

23 Oct 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: J&J and Roche's first-half wins and challenges; Alexion's Ultomiris plans; GSK's AI and genomics investments; and a wide-ranging chat with the former secretary of the US department of Veterans Affairs.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 21 October 2022, including: [Johnson & Johnson](#) and [Roche Holding AG](#)'s first-half wins and challenges; [Alexion Pharmaceuticals Inc.](#)'s Ultomiris plans; [GSK plc](#)'s AI and genomics investments; and a wide-ranging chat with the former secretary of the US department of Veterans Affairs.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[With Stelara's Star Set To Fade, J&J Assures Investors It Will Grow Anyway](#)" - Scrip, 18 Oct, 2022.)

(Also see "[Vabysmo Is Bright Spot For Roche In Bumpy Q3](#)" - Scrip, 18 Oct, 2022.)

(Also see "[Alexion's Ultomiris Expands Its Reach As Soliris Biosimilars Loom](#)" - Scrip, 17 Oct, 2022.)

(Also see "[GSK's New Research Chief Begins Leadership With Expanded Genomics/AI Alliance](#)" - Scrip, 18 Oct, 2022.)

(Also see "[*US Price Control, Outcomes-Based Contracting: Reflections Of Former VA Secretary Shulkin*](#)" - Scrip, 17 Oct, 2022.)

[*Click here to explore this interactive content online*](#) ✎